Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates

Core Insights - Charles River Laboratories (CRL) reported quarterly earnings of $2.59 per share, exceeding the Zacks Consensus Estimate of $2.43 per share, but down from $2.72 per share a year ago [1] - The company achieved a revenue of $1.01 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.33%, although it is a decrease from $1.03 billion year-over-year [3] Earnings Performance - The earnings surprise for the quarter was 6.58%, following a previous quarter where the company reported earnings of $2.80 per share against an expectation of $2.39, resulting in a surprise of 17.15% [2] - Over the last four quarters, Charles River has consistently surpassed consensus EPS estimates [2] Revenue Insights - The company has also exceeded consensus revenue estimates in four consecutive quarters [3] - The current consensus EPS estimate for the upcoming quarter is $2.51, with expected revenues of $976.3 million, and for the current fiscal year, the estimate is $10.01 on $3.99 billion in revenues [8] Market Performance - Charles River shares have declined approximately 20.2% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [4] - The Zacks Industry Rank places Medical Services in the bottom 46% of over 250 Zacks industries, indicating potential challenges for stock performance [9] Future Outlook - The company's earnings outlook will be influenced by management's commentary during the earnings call, and the trend of estimate revisions is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock [5][7] - Investors are encouraged to monitor changes in earnings estimates for the upcoming quarters, as these can significantly impact stock performance [6][8]